Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised

MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Open original source
MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Open original source